Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Ill-defined disorder? 4,411 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 4,411 reports of Ill-defined disorder have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 4.5% of all adverse event reports for TOCILIZUMAB.

4,411
Reports of Ill-defined disorder with TOCILIZUMAB
4.5%
of all TOCILIZUMAB reports
1,226
Deaths
2,066
Hospitalizations

How Dangerous Is Ill-defined disorder From TOCILIZUMAB?

Of the 4,411 reports, 1,226 (27.8%) resulted in death, 2,066 (46.8%) required hospitalization, and 1,272 (28.8%) were considered life-threatening.

Is Ill-defined disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 4,411 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Ill-defined disorder?

ACETAMINOPHEN\OXYCODONE (9,780) ACETAMINOPHEN\HYDROCODONE (6,159) RITUXIMAB (4,220) ETANERCEPT (4,202) METHOTREXATE (4,063) ABATACEPT (3,630) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (3,600) LEFLUNOMIDE (3,570) CERTOLIZUMAB PEGOL (3,273) GOLIMUMAB (3,122)

Which TOCILIZUMAB Alternatives Have Lower Ill-defined disorder Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Ill-defined disorder Reports All Drugs Causing Ill-defined disorder TOCILIZUMAB Demographics